Cargando…
Unilateral axillary Adenopathy in the setting of COVID-19 vaccine
With the recent U.S. Food and Drug Administration (FDA)-approval and rollout of the Pfizer-BioNTech and Moderna COVID-19 vaccines, it is important for radiologists to consider recent COVID-19 vaccination history as a possible differential diagnosis for patients with unilateral axillary adenopathy. H...
Autores principales: | Mehta, Nishi, Sales, Rachel Marcus, Babagbemi, Kemi, Levy, Allison D., McGrath, Anika L., Drotman, Michele, Dodelzon, Katerina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817408/ https://www.ncbi.nlm.nih.gov/pubmed/33486146 http://dx.doi.org/10.1016/j.clinimag.2021.01.016 |
Ejemplares similares
-
Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up
por: Mehta, Nishi, et al.
Publicado: (2021) -
Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023) -
Transient ipsilateral breast edema following COVID-19 vaccination
por: McGrath, Anika L., et al.
Publicado: (2022) -
Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation
por: Igual-Rouilleault, Alba Cristina, et al.
Publicado: (2021) -
Invited Commentary: Evolving Management of COVID-19
Vaccine–related Axillary Adenopathy
por: Weinstein, Susan
Publicado: (2022)